.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC14_Sarilumab.Sarilumab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC14_Sarilumab.Sarilumab| name: | Sarilumab |
| ATC code: | L04AC14 | route: | subcutaneous |
| n-compartments | 2 |
Sarilumab is a human monoclonal antibody that binds to the interleukin-6 (IL-6) receptor, inhibiting IL-6 mediated signaling. It is used primarily for the treatment of moderate to severe rheumatoid arthritis in adults who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). Sarilumab is approved for use in several regions including the United States and Europe.
Pharmacokinetic parameters reported in healthy subjects and patients with rheumatoid arthritis receiving subcutaneous sarilumab 200 mg. Data chiefly derived from published phase III studies and population PK analyses.
Xu, C, et al., & Kanamaluru, V (2019). Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis. Clinical pharmacokinetics 58(11) 1455–1467. DOI:10.1007/s40262-019-00765-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31055792
Ishii, T, et al., & Takahashi, T (2023). Pharmacokinetics, pharmacodynamics, and safety of single-dose subcutaneous sarilumab with or without methotrexate in Japanese patients with rheumatoid arthritis: Two single-dose studies. Modern rheumatology 33(2) 279–291. DOI:10.1093/mr/roac036 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35445719
Ma, L, et al., & Kanamaluru, V (2020). Population Pharmacokinetic-Pharmacodynamic Relationships of Sarilumab Using Disease Activity Score 28-Joint C-Reactive Protein and Absolute Neutrophil Counts in Patients with Rheumatoid Arthritis. Clinical pharmacokinetics 59(11) 1451–1466. DOI:10.1007/s40262-020-00899-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32451909